 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jun 05, 2021 |
| Title |
DRUGseq U2OS cells treated with small molecules |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We report the transcriptional changes associated with treatment of U2OS osteosarcoma cell line with DMSO, ND-09-QY33, CA-90-VK59, JC-68-AL90, MB-03-IE36, JC-43-ZO95, PA-33-CK45, KA-73-NB69, QC-05-UB63, SE-15-AV21, NV-67-DX31, DB-85-YA47, NA-37-JQ34, VA-76-OV33, & LD-22-SA99
|
| |
|
| Overall design |
U2OS cells were treated with 3.18nM, 10.04nM, 31.74nM, 100.29nM, 316.91nM, 1001.44nM, 3164.56nM, and 10000nM of DMSO, ND-09-QY33, CA-90-VK59, JC-68-AL90, MB-03-IE36, JC-43-ZO95, PA-33-CK45, KA-73-NB69, QC-05-UB63, SE-15-AV21, NV-67-DX31, DB-85-YA47, NA-37-JQ34, VA-76-OV33, & LD-22-SA99 for 24 hrs and subjected to DRUGseq
Please note that a github repository has been created to assist in all downstream analysis:
https://github.com/Novartis/DRUG-seq
|
| |
|
| Contributor(s) |
Ho DJ, Henault M, Yang C, Russ C, Lindemann A |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jun 04, 2021 |
| Last update date |
Jun 07, 2021 |
| Contact name |
Daniel Ho |
| E-mail(s) |
daniel.ho@novartis.com
|
| Organization name |
Novartis Institutes for Biomedical Research
|
| Street address |
250 Massachusetts Avenue
|
| City |
Cambridge |
| ZIP/Postal code |
02139 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
| Samples (9)
|
|
| Relations |
| BioProject |
PRJNA735181 |
| SRA |
SRP322709 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE176150_RAW.tar |
138.1 Mb |
(http)(custom) |
TAR (of RDATA, TXT) |
| GSE176150_metadata.csv.gz |
41.9 Kb |
(ftp)(http) |
CSV |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...